Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue… - Blood …, 2018 - ashpublications.org
Very low–dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid
(ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary …
被引用次数：44 相关文章
[HTML] nih.gov

[HTML][HTML] Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue… - Blood …, 2018 - ncbi.nlm.nih.gov
Very low–dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid
(ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary …

Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction

O Borst, P Munzer, N Alnaggar, S Geue… - Blood …, 2018 - cris.maastrichtuniversity.nl
Very low-dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid (ASA)
and clopidogrel, is associated with improved outcomes in patients with acute coronary …

Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.

O Borst, P Münzer, N Alnaggar, S Geue… - Blood …, 2018 - europepmc.org
Very low–dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid
(ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary …

Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue… - BLOOD …, 2018 - publicatt.unicatt.it
Very low-dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid (ASA)
and clopidogrel, is associated with improved outcomes in patients with acute coronary …

Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue, R Tegtmeyer… - Blood Advances, 2018 - Elsevier
Very low–dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid
(ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary …
[PDF] mlm-labs.com

[PDF][PDF] Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue, R Tegtmeyer… - 2018 - mlm-labs.com
Platelets are critically involved in the pathophysiology of coronary thrombosis and
atheroprogression. 1, 2 Factor Xa (FXa) inhibition on top of dual-antiplatelet therapy (DAPT) …

Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue… - Blood …, 2018 - pubmed.ncbi.nlm.nih.gov
Very low-dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid (ASA)
and clopidogrel, is associated with improved outcomes in patients with acute coronary …
[PDF] researchgate.net

[PDF][PDF] Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

O Borst, P Münzer, N Alnaggar, S Geue, R Tegtmeyer… - 2018 - researchgate.net
Platelets are critically involved in the pathophysiology of coronary thrombosis and
atheroprogression. 1, 2 Factor Xa (FXa) inhibition on top of dual-antiplatelet therapy (DAPT) …

[引用][C] Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction

O Borst, P Muenzer, N Alnaggar… - Blood …, 2018 - tobias-lib.ub.uni-tuebingen.de
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction …